DALLAS, December 8, 2014 /PRNewswire/ --
RnRMarketResearch.com adds "Hemorrhagic Fever - Pipeline Review, H2 2014" and "Hemorrhagic Fever Global Clinical Trials Review, H2, 2014" market research reports in the pharmaceuticals intelligence collection of its online business intelligence library.
The Hemorrhagic Fever Global Clinical Trials Review, H2, 2014 research report provides elemental information and data relating to the clinical trials on Hemorrhagic Fever. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hemorrhagic Fever. Complete research is available at http://www.rnrmarketresearch.com/hemorrhagic-fever-global-clinical-trials-review-h2-2014-market-report.html .
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of this global clinical trials review report for Hemorrhagic Fever includes data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type and listings of discontinued trials (suspended, withdrawn and terminated).
Companies like Sanofi, Sarepta Therapeutics Inc., GlaxoSmithKline plc, Liaoning Cheng Da Biotechnology Co. Ltd, U.S. Army Medical Research and Materiel Command, The National Institute of Allergy and Infectious Diseases and University of Maryland are discussed in this research available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=248718 .
The Hemorrhagic Fever - Pipeline Review, H2 2014 research report provides comprehensive information on the therapeutic development for Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report (http://www.rnrmarketresearch.com/hemorrhagic-fever-pipeline-review-h2-2014-market-report.html ) may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope of the Hemorrhagic Fever - Pipeline Review, H2 2014 report covers a snapshot of the global therapeutic landscape of Hemorrhagic Fever, review of key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities as well as reviews of key players involved in the therapeutics development for Hemorrhagic Fever and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources is provided along with pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects as well as coverage of the Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products are covered in this research.
Companies Involved in Hemorrhagic Fever Therapeutics Development and discussed in this research include Adamas Pharmaceuticals Inc., AlphaVax Inc., Arbovax Inc., BioCryst Pharmaceuticals Inc., Chimerix Inc., Crucell N.V., Epirus Biopharmaceuticals Inc., Evolva SA, FIT Biotech Oyj, GeoVax Labs Inc., GlaxoSmithKline plc, Hawaii Biotech Inc., Hemispherx Biopharma Inc., Humabs BioMed SA, iBio Inc., Immunovaccine Inc., Inovio Pharmaceuticals Inc., Integrated BioTherapeutics Inc., Janssen Pharmaceuticals Inc., Medicago Inc., Microbiotix Inc., Myelo Therapeutics GmbH, NanoViricides Inc., Navigen Pharmaceuticals Inc., NewLink Genetics Corporation, Novavax Inc., Panacea Biotec Limited, Peregrine Pharmaceuticals Inc., Profectus BioSciences Inc., Sarepta Therapeutics Inc., SIGA Technologies Inc., Sihuan Pharmaceutical Holdings Group Ltd., SKAU Vaccines ApS, Summit Corporation plc, Tekmira Pharmaceuticals Corp., Themis Bioscience GmbH, Toyama Chemical Co. Ltd. and Vaxart Inc. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=248260 .
Explore more reports on the pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
SOURCE RnR Market Research